Contact
searchSearch
HMP Global

Respiratory Syncytial Virus Topic Center

Featured Article

News
Long-Term Effectiveness of RSV Vaccine Declines Over Two Seasons, VHA Study Finds
11/25/2025
Grace Taylor, MS, MA
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health...
11/25/2025
Pharmacy Learning Network
News
RSV Vaccination Rates Remain Low Among US Veterans
11/19/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus...
11/19/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Shows Strong Safety Profile in Adults, Global Analysis Finds
11/14/2025
Grace Taylor, MS, MA
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds...
11/14/2025
Pharmacy Learning Network
News
Primary Care Providers Drive RSV Vaccine Uptake Among Older Adults
11/12/2025
Grace Taylor, MS, MA
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey...
11/12/2025
Pharmacy Learning Network
News
RSV Poses Significant Threat to Patients With Systemic Autoimmune Rheumatic Diseases
10/31/2025
Grace Taylor, MS, MA
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune...
10/31/2025
Pharmacy Learning Network
News
Dual RSV and Influenza Vaccination Reduces Health Care Utilization and Costs Among Older Adults
10/31/2025
Juliet Gallagher
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study...
10/31/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Proves Highly Effective Against Severe RSV in Older Adults
10/29/2025
Grace Taylor, MS, MA
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser...
10/29/2025
Pharmacy Learning Network
News
RSV Poses Sixfold Higher Hospitalization and Death Risk for Long-Term Care Residents
10/21/2025
Lisa Kuhns, PhD, MD
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term...
10/21/2025
Pharmacy Learning Network
News
RSV Vaccines Cut Hospitalizations in Older Adults but Show Gaps in High-Risk Groups
09/29/2025
Grace Taylor, MS, MA
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds...
09/29/2025
Pharmacy Learning Network
News
RSV Pneumonia Leads to Elevated ICU Admissions and Mortality in Older Adults
08/08/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus...
08/08/2025
Pharmacy Learning Network
News
Comorbidities Drive ICU Admission and Mortality in RSV and HMPV Among Older Adults
07/16/2025
Grace Taylor, MS, MA
A Colorado study reveals distinct comorbidity-driven risks for ICU admission and mortality in older adults hospitalized with respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).]
A Colorado study reveals distinct comorbidity-driven risks for ICU admission and mortality in older adults hospitalized with respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).]
A Colorado study reveals...
07/16/2025
Pharmacy Learning Network

Newsfeed

News
Long-Term Effectiveness of RSV Vaccine Declines Over Two Seasons, VHA Study Finds
11/25/2025
Grace Taylor, MS, MA
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health Administration (VHA) study shows that respiratory syncytial virus (RSV) vaccine protection in older adults remains strong initially but declines substantially over 18 months, especially among immunocompromised...
A large US Veterans Health...
11/25/2025
Pharmacy Learning Network
News
RSV Vaccination Rates Remain Low Among US Veterans
11/19/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus (RSV) vaccination rates among US veterans remain low, exposing persistent gaps in preventive care despite widespread eligibility and no-cost access through the Veterans Health Administration (VHA), according to a...
Respiratory syncytial virus...
11/19/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Shows Strong Safety Profile in Adults, Global Analysis Finds
11/14/2025
Grace Taylor, MS, MA
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds bivalent RSVpreF vaccine safe and well tolerated in adults, reinforcing its role in protecting against respiratory syncytial virus infection.
A large global analysis finds...
11/14/2025
Pharmacy Learning Network
News
Primary Care Providers Drive RSV Vaccine Uptake Among Older Adults
11/12/2025
Grace Taylor, MS, MA
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey study reveals that primary care providers are the leading influence driving older adults to receive the respiratory syncytial virus (RSV) vaccine, highlighting a key opportunity for pharmacists to boost...
A prospective multisite survey...
11/12/2025
Pharmacy Learning Network
News
RSV Poses Significant Threat to Patients With Systemic Autoimmune Rheumatic Diseases
10/31/2025
Grace Taylor, MS, MA
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune rheumatic diseases face high hospitalization rates from RSV, according to study published in Seminars in Arthritis and Rheumatism.
Patients with autoimmune...
10/31/2025
Pharmacy Learning Network
News
Dual RSV and Influenza Vaccination Reduces Health Care Utilization and Costs Among Older Adults
10/31/2025
Juliet Gallagher
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study using the Humana Healthcare Research database highlights the significant clinical and economic benefits of respiratory syncytial virus (RSV) vaccination among older adults in the US.
A new retrospective cohort study...
10/31/2025
Pharmacy Learning Network
News
RSVpreF Vaccine Proves Highly Effective Against Severe RSV in Older Adults
10/29/2025
Grace Taylor, MS, MA
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser Permanente Southern California shows that Pfizer’s RSVpreF vaccine provides strong protection against severe respiratory syncytial virus (RSV)–related illness and hospitalizations in older adults, including...
A real-world study led by Kaiser...
10/29/2025
Pharmacy Learning Network
News
RSV Poses Sixfold Higher Hospitalization and Death Risk for Long-Term Care Residents
10/21/2025
Lisa Kuhns, PhD, MD
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term care facilities face a dramatically higher risk of severe illness and death from respiratory syncytial virus (RSV) than their community-dwelling peers, according to new data published in The Journal of the...
Older adults living in long-term...
10/21/2025
Pharmacy Learning Network
News
RSV Vaccines Cut Hospitalizations in Older Adults but Show Gaps in High-Risk Groups
09/29/2025
Grace Taylor, MS, MA
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds respiratory syncytial virus (RSV) vaccines significantly reduce hospitalizations in adults 60 and older, though protection wanes over time and is weaker in immunocompromised patients and those with cardiovascular...
A new 2-season study finds...
09/29/2025
Pharmacy Learning Network
News
RSV Pneumonia Leads to Elevated ICU Admissions and Mortality in Older Adults
08/08/2025
Grace Taylor, MS, MA
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus (RSV) pneumonia leads to high intensive care unit (ICU) admission and mortality rates in older adults, rivaling those of influenza and human metapneumovirus, according to a study published in the Journal of...
Respiratory syncytial virus...
08/08/2025
Pharmacy Learning Network
PharmLaw
Iowa Attorney General Accuses Insulin Makers and PBMs of Deceptive Pricing Practices
02/03/2026
Juliet Gallagher
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna...
02/03/2026
Pharmacy Learning Network
News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
PharmLaw
PCMA Sues California Over SB 41, Challenging PBM Fiduciary Duties Under ERISA
01/27/2026
Juliet Gallagher
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious...
01/27/2026
Pharmacy Learning Network
News
Recall Issued for Diclofenac Sodium Topical Gel Due to pH Specification Failure
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
Furosemide 40 mg Tablets Recalled Due to Foreign Substance Contamination
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
PharmLaw
Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged GLP-1 Antitrust Violations
01/21/2026
Juliet Gallagher
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding...
01/21/2026
Pharmacy Learning Network
News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use